

Health Sciences



U M 6 S S
EDITIONS

Volume 1 | Issue 1

Article 9

Antiplasmodial Activity of Ketotifen-Artemether-Lumefantrine on Plasmodium Berghei Infected Mice

Udeme O. Georgewill

Department of Pharmacology, Faculty of Clinical Sciences, University of Port Harcourt, Rivers State, Nigeria, udgeorgewill@yahoo.com

Chidi E. Ezerioha

Department of Pharmacology, Faculty of Clinical Sciences, University of Port Harcourt, Rivers State, Nigeria

Elias Adikwu

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Niger Delta University, Bayelsa State, Nigeria

Follow this and additional works at: <https://journal.um6ss.ma/health-sciences>



Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Georgewill, Udeme O.; Ezerioha, Chidi E.; and Adikwu, Elias (2020) "Antiplasmodial Activity of Ketotifen-Artemether-Lumefantrine on Plasmodium Berghei Infected Mice," *Health Sciences*: Vol. 1: Iss. 1, Article 9.

Available at: <https://doi.org/10.15342/hs.2020.245>

This Research Article is brought to you for free and open access by Health Sciences. It has been accepted for inclusion in Health Sciences by an authorized editor of Health Sciences.

RESEARCH ARTICLE

Antiplasmodial Activity of Ketotifen-Artemether-Lumefantrine on *Plasmodium Berghei* Infected Mice

Udeme O. Georgewill ^a, Chidi E. Ezerioha^a, Elias Adikwu^b^a Department of Pharmacology, Faculty of Clinical Sciences, University of Port Harcourt, Rivers State, Nigeria^b Department of Pharmacology and Toxicology, Faculty of Pharmacy, Bayelsa State University, Bayelsa State, Nigeria**ABSTRACT**

Introduction: The development of new antimalarial drugs is time-consuming and costly, thus repurposing of drugs with initial indications for possible antimalarial indication is imperative. This study assessed the antiplasmodial effect of ketotifen (KT) in combination with artemether/lumefantrine (A/L) in *Plasmodium berghei* infected mice.

Materials and Methods: Adult mice (25-30g) were parasitized with *Plasmodium berghei*, grouped and treated per oral (p.o) with KT (0.1mg/kg), A/L (2.3/13.7mg/kg) and KT/A/L daily in curative, suppressive and prophylactic studies. The negative control (NC) and the positive control (PC) were treated daily p.o with normal saline (0.2mL) and chloroquine (CQ) (10mg/kg) for 4 days respectively. After treatment, blood samples were collected and assessed for percentage parasitemia level, hematological and lipid parameters.

Results: The curative, suppressive and prophylactic studies showed significant decreases in percentage parasitemia levels at KT (0.1mg/kg) ($p < 0.01$), A/L (2.3/13.7 mg/kg) ($p < 0.001$) and KT/A/L ($p < 0.0001$) when compared to negative control. Significant increases in mean survival times occurred at KT (0.1 mg/kg) ($p < 0.01$), A/L (2.3/13.7mg/kg) ($p < 0.001$) and A/L/T ($p < 0.0001$) when compared to negative control. Significant increases in pack cell volume, red blood cells, hemoglobin, high density lipoprotein cholesterol levels with significant decreases in total cholesterol, white blood cells, low density lipoprotein cholesterol and triglyceride levels at KT (28.6 mg/kg) ($p < 0.05$), A/L (2.3/13.7mg/kg) ($p < 0.01$) and KT/A/L ($p < 0.001$) when compared to negative control.

Conclusion: KT may be repurposed in combination with A/L for malaria treatment.

KEYWORDS: Ketotifen; Artemether/Lumefantrine; Antiplasmodium; Mice.

Correspondence: Pr Ogunwari Georgewill Udeme, Department of Pharmacology, Faculty of Clinical Sciences, University of Port Harcourt, Rivers State, Nigeria. Email: udgeorgewill@yahoo.com

Copyright © 2020 Udemi OG et al. This is an open access article distributed under the [Creative Commons Attribution 4.0 International](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Malaria is among the ailments ravaging the human race and its manifestations could be severe and life-threatening. Its major impact is most experienced in developing countries [1]. In 2018, malaria infection was 228 million which accounted for over 405000 deaths with most in developing nations. The impact of malaria and its consequence is predominant in children below the age of five and pregnant women which poses significant health challenge [2]. Efforts to eradicate malaria have experienced setbacks due to challenges including the emergence of insecticide-resistant mosquitoes, drug-resistant parasites and lack of drugs or vaccines to block parasite transmission [3]. Drug resistance has remarkably increased causing changes in malaria treatment from chloroquine (CQ) to artemisinin-based combination

therapies (ACTs), which are currently preferred for malaria treatment. Despite the antimalarial impact of ACTs, setbacks due to cost and emergence of resistant parasites herald the need for newer antimalaria drugs with mode of action and different structural features [4].

One of the strategies to discover new antimalarial is to reposition, or repurpose drugs that are already used for other indications [5]. This approach, as compared to the “*de novo*” drug discovery process has advantages such as reduced cost and short time of drug development [5]. Repurposed drugs have well-documented toxicity, pharmacology and drug-drug interaction profile. Drug repurposing is based on the principle of polypharmacology; a paradigm in drug discovery where a drug with multiple targets and off-target effects may have

multiple mechanisms of action [6]. The repositioning of drugs with good safety profiles will gain quick approval for newer indications using the same route of administration [7]. It is encouraging that drug regulatory associations in Europe and USA have launched drug repurposing programs to identify new uses for existing medications [8].

Ketotifen (KT), a tricyclic benzocycloheptathiophene derivate, is broadly used for allergy, asthma, and inflammatory disorders. It blocks H1 receptors, stabilizes mast cells, and inhibits eosinophil accumulation and degranulation that results in the further stabilization of the cell membrane [9]. It is well absorbed after oral administration, with peak plasma drug concentrations within 2 to 4 h [10]. In a recent study both KT and its metabolite norketotifen were shown to be active against schizonts and liver-stage *P. berghei* parasites [11]. KT and other antihistamines have been shown to be effective in reversing CQ resistance in *P. falciparum* [12,13] and *P. yoelii nigeriensis* [14]. It shows higher potency in blocking oocyst formation in mice, which suggests that KT may act more effectively on mosquito stages of fertilization. KT affects gamete production by decreasing *P. falciparum* gametocytes and greatly reduced the numbers of exflagellation centers [3]. Study shows the possible role of KT in the treatment of *P. falciparum* associated malaria in combination with CQ [15]. This study, assessed the antiplasmodial activity of KT in combination with artemether/ lumefantrine (A/L) in *P. berghei* infected mice.

MATERIALS AND METHODS

Experimental Animals and Malaria Parasite.

Wistar mice weighing 25- 30g were used. The mice were bought from the animal house of the Department of Pharmacology, University of Port-Harcourt, Nigeria The mice were kept in cages and allowed to acclimatize for 2 weeks before the study began. The mice were fed with food and water *ad libitum*. *P. berghei* was gotten from Malaria Research Laboratory, Centre for Malaria Research and Phytomedicine, University of Port-Harcourt, Nigeria. The directive (2010/63/EU) of the European Union Parliament and the Council on the handling of laboratory animals for scientific purposes was used for this study.

Drugs.

Ketotifen (KT) (Sun Pharm Industries Ltd, India), artemether/lumefantrine (A/L) (IPCA Laboratories Ltd), and Chloroquine (CQ) (Evans Medical Nigeria Plc) were used for this study. A/L (2.3/13.7 mg/kg) [16], Ketotifen (0.1 mg/kg) [17] and CQ (10mg/kg) [18] were used.

Parasite Inoculation.

Blood samples from mice were first screened to ascertain that they were parasite free. Stock inoculum of $1 \times 10^7 P. berghei$ infected erythrocytes in 0.2 mL was prepared by diluting portions of the blood infected with *P. berghei* with 0.9% normal saline. This was inoculated into each mouse via intra-peritoneal route of administration.

Curative Test.

The method proposed by Ryley and Peters (1970) [19] was used for this study. Thirty mice (Groups I-VI) were used. Groups I-VI were inoculated with $1 \times 10^7 P. berghei$ parasitized erythrocytes intraperitoneally (i.p). After 72 hours (3 days), the mice were treated as follows. Group I (Non-parasitized) (Normal control), and group II (Negative control) were treated with normal saline (0.2mL) respectively. Group III (Positive control) was treated with CQ (10mg/kg) whereas groups IV – VI were treated with KT (0.1 mg/kg), A/L (1.1/4.6mg/kg) and KT/A/L for 4 days respectively. On day 5, tail blood samples were collected and thin blood films were made on microscope slides. The films were fixed with methanol and stained with 10% Geimsa stain for 30 minutes. The stained thin blood films were viewed under oil immersion x100 magnification and the number of parasitized red blood cells were counted against the total number of red blood cells in a field and percentage parasitemia calculated using the formula shown below.

Suppressive Test.

This test was conducted for four days as reported by Knight and Peters (1980) [20]. The mice were inoculated i.p with blood sample (0.2mL) containing $1 \times 10^7 P. berghei$. Afterward, the mice were randomized into 5 groups of five mice. After 3 hours, the mice were treated. Group I (Negative control) was treated daily with normal saline (0.2mL) whereas group II (Positive control) was treated with CQ (10mg/kg) for 4 days. Groups III - V were treated daily with KT (0.1 mg/kg), A/L (1.1/4.6mg/kg) and KT/A/L for 4 days respectively. On day 5, blood samples were collected, films were prepared and percentage parasitemia determined using the formula below

Prophylactic Test.

This was evaluated according to Peters (1965) [21]. Twenty five mice were randomized into 5 groups of five mice each. Group I (Negative control) and group II (Positive control) were administered daily with normal saline (0.2mL) and CQ (10mg/kg) respectively. Groups III – V were administered daily with KT (0.1 mg/kg), A/L (1.1/4.6mg/kg) and KT/A/L respectively. On day 4, the mice were infected i.p. with $1 \times 10^7 P. berghei$ parasitized erythrocytes and treatment continues for 4 days. Blood samples were collected from the tail on day 5 and day 7 and percentage parasitemia determined using the formula below :

$$\% \text{ Parasitemia} = \frac{\text{Total number of parasitized RBC}}{\text{Total number of RBC}} \times 100$$

$$\% \text{ Inhibition} = \frac{(\text{Mean parasitemia of negative control} - \text{Mean parasitemia of treated groups})}{\text{Mean parasitemia of negative control}} \times 100$$

Determination of Mean Survival.

During the study, the mice were observed for mortality which was determined as mean (MST) in days using the formula below

$$\text{MST} = \frac{\text{Sum of survival time (days) of all the mice in the group}}{\text{Total number of mice in that group}}$$

Evaluation of hematological and lipid parameters.

Blood samples from the curative test were evaluated for Red blood cell (RBC), hemoglobin (HB), pack cell volume (PCV), high density lipoprotein cholesterol (HDL-C), white blood cell (WBC), triglyceride (TG), total cholesterol (CHOL) and high density lipoprotein cholesterol (LDL-C) levels using an auto analyzer

Data Analysis.

Data was analyzed using GraphPad prism 6.0 statistical software. Data was presented as Mean±SEM. Significant difference was considered using one-way analysis of variance (ANOVA) followed by *Tukey's* post-hoc test. Significance was considered at $p<0.05$; $p<0.01$ and $p<0.001$.

RESULTS

Curative test

Curative test shows significant decreases in percentage parasitemia at $p<0.01$ and $p<0.001$ in mice treated with individual doses of KT and A/L respectively when compared to negative control. However, most significant reduction in percentage parasitemia level at $p<0.0001$ occurred in mice treated with KT/A/L when compared to negative control. The observed decrease in percentage parasitemia in KT/A/L treated mice differ ($p<0.05$) when compared to CQ-treated mice (**Table 1**). Percentage parasitemia inhibition were 62.5% and 73.7 % in rats treated with individual doses of KT and A/L with observed significance at $p<0.01$ and $p<0.001$ respectively when compared to negative control. On the other hand, 90.0 % parasitemia inhibition was observed in KT/A/L treated mice which differ at $p<0.0001$ when compared to negative control (**Table 1**). Treatment with KT, AL, KT/A/L significantly increased MST at $p<0.05$, $p<0.01$, and $p<0.001$ respectively when compared to negative control (**Table 1**).

Suppressive Test.

In the suppression test, individual doses of KT and A/L produced significant reductions in percentage parasitemia levels at $p<0.01$ and $p<0.001$ respectively when compared to negative control. On the hand, KT/A/L produced most significant reduction in percentage parasitemia level at $p<0.0001$ when compared to negative control. Comparatively, reduction in percentage parasitemia produced by A/L/KF differ ($p<0.05$) from CQ (**Table 2**). Treatment with KT, A/L and KT/A/L produced 68.0%, 75.0 % and 91. 9% percentage parasitemia inhibitions respectively (**Table 2**). MST was significantly increased in mice treated with KT ($p<0.05$), A/L ($p<0.01$) and KT/A/L ($p<0.001$) when compared to negative control (**Table 2**).

Prophylactic Test.

Treatment individual doses of KT and A/L produced significant time-dependent reductions in percentage

parasitemia levels on day 5 and 7 when compared to negative control. However, treatment with KT/A/L produced most significant time-dependent reductions in percentage parasitemia levels on day 5 and day 7 when compared to negative control (**Table 3**). On day 7, individual doses of KT and A/L produced 84.4% and 89.4 % percentage parasitemia inhibition respectively, KT/A/L produced 99.3 percentage parasitemia inhibition whereas CQ (Positive control) produced 91.8 % percentage parasitemia inhibition (**Table 3**). MST was significantly increased in mice treated with KT ($p<0.05$), A/L ($p<0.01$) and KT/A/L ($p<0.001$) when compared to negative control (**Table 2**).

Effects on Hematological and Lipid Parameters.

The negative control shows significant decreases in RBC, HB, PCV and HDL levels with increases in WBC, TG, CHOL, LDL-C levels when compared to non-parasitized rats (normal control). In contrast, RBC, HB, PCV were significantly increased whereas WBC, TG, CHOL, LDL-C were significantly decreased at $p<0.01$ and $p<0.001$ by KT and A/L respectively when compared to negative control (**Tables 4 and 5**). However, KT/A/L produced most significant increases in RBC, HB, PCV and HDL-C levels with decreases in WBC, TG, CHOL, LDL-C levels ($p<0.0001$) when compared to negative control (**Tables 4 and 5**). The observed effects produced by KT/A/L on RBC, HB, PCV, HDL-C, WBC, TG, CHOL, LDL-C levels differ ($p<0.05$) when compared to CQ (**Tables 4 and 5**).

Table 1: Curative Activity of Ketotifen and its Combination with artemether/ lumefantrine on *Plasmodium Berghei*-Infected Mice.

Group	Parasitemia (%)	MST	Inhibition (%)
NC	22.8±0.59	7.75±0.85	-
CQ	5.85±0.21 ^a	25.0±2.03 ^b	74.3
KT	8.55±0.19 ^b	20.5±2.29 ^d	62.5
A/L	6.00±0.22 ^a	26.0±2.05 ^b	73.7
KT/A/L	2.28±0.25 ^{cd}	31.0±1.92 ^a	90.0

With the following referring to :

NC: Negative Control; CQ: Chloroquine; KT: Ketotifen; A/L: Artemether /Lumefantrine; KT/A/L: Ketotifen/Artemether/Lumefantrine; MST: Mean Survival Time; n=5; Data expressed as mean ± SEM, ^a $p<0.001$ when compared to NC; ^b $p<0.01$ when compared to NC; ^c $p<0.0001$ when compared to NC; ^d $p<0.05$ when compared to CQ.

Table 2: Suppressive Activity of Ketotifen and its Combination with Artemether/lumefantrine on *Plasmodium Berghei*-Infected Mice.

Group	Parasitemia (%)	MST	Inhibition (%)
NC	12.5±1.73	8.00±1.08	-
CQ	2.40±0.10 ^a	28.0±3.22 ^b	80.8
KT	4.00±0.29 ^b	22.7±1.11 ^d	68.0
A/L	3.12±0.19 ^a	28.2±2.52 ^b	75.0
KT/A/L	1.01±0.21 ^{cd}	35.0±3.68 ^a	91.9

With the following referring to :

NC: Negative Control; CQ: Chloroquine; KT: Ketotifen; A/L: Artemether /Lumefantrine; KT/A/L: Ketotifen/Artemether/Lumefantrine; MST: Mean Survival Time; n=5; Data expressed as mean ± SEM, ^a $p<0.001$ when compared to NC; ^b $p<0.01$ when compared to NC; ^c $p<0.0001$ when compared to NC; ^d $p<0.05$ when compared to CQ.

Table 3: Prophylactic Activity of ketotifen and its Combination with Artemether/ Lumefantrine on *Plasmodium Berghei*-infected Mice.

Grp.	Parasite-mia (%)	Inhibi-tion (%)	Parasite-mia (%)	Inhibition (%)	MST
	Day 5	Day 5	Day 7	Day 7	
NC	9.80±0.93		16.5±1.07	-	8.00±0.47
CQ	1.80±0.29 ^a	81.6	1.35±0.14 ^a	91.8	30.7±2.33 ^b
KT	3.00±0.48 ^b	69.3	2.58±0.24 ^b	84.4	22.9±2.91 ^d
A/L	2.20±0.61 ^a	77.5	1.75±0.14 ^a	89.4	26.4±3.44 ^b
KT/A/L	0.21±0.50 ^{cd}	95.9	0.10±0.16 ^{cd}	99.3	34.5±2.18 ^a

With the following referrin to : NC: Negative Control; CQ: Chloroquine; KT: Ketotifen; A/L: Artemether /Lumefantrine; KT/A/L: Ketotifen/Artemether/Lumefantrine; MST: Mean Survival Time; n=5; Data expressed as mean ± SEM, ^ap<0.001 when compared to NC; ^bp<0.01 when compared to NC; ^cp<0.0001 when compared to NC; ^dp<0.05 when compared to CQ.

Table 4: Effect of Ketotifen and its Combination with Artemether/lumefantrine on Lipid Profile of *Plasmodium berghei*-infected Mice.

Trtmnt.	TG (mg/dL)	CHOL (mg/dL)	HDL-C (mg/dL)	LDL-C (mg/dL)
MC	114.1±7.03	156.3±9.21	56.1±2.91	2.21±0.30
NC	300.5±11.2	371.1±14.2	23.9±1.26	6.98±0.48
CQ	184.0±8.87 ^a	228.2±12.2 ^a	50.1±1.92 ^a	3.70±0.33 ^a
KT	230.4±6.39 ^b	270.0±11.0 ^b	40.9±1.82 ^b	4.77±0.15 ^b
AL	200.4±9.01 ^a	247.7±10.1 ^a	48.7±1.51 ^a	3.50±0.21 ^a
KT/A/L	138.7±5.91 ^{cd}	174.9±12.9 ^{cd}	53.77±2.52 ^a	2.32±0.36 ^{cd}

With the following referring to : MC: Normal control; NC: Negative control; CQ: Chloroquine; KT: Ketotifen A/L: Artemether/lumefantrine, KT/A/L: Ketotifen/Artemether/Lumefantrine; TG: Triglyceride; CHOL: Total cholesterol; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; n=5; Values are expressed as M±SEM, ^ap<0.01 when compared to NC; ^bp<0.05 when compared to NC; ^cp<0.001 when compared to NC; ^dp<0.01 when compared to CQ.

Table 5: Effect of ketotifen and its combination with artemether/lumefantrine on hematological parameters of *Plasmodium berghei*-infected Mice.

Trmt.	RBC(×10 ⁶ /μl)	WBC(×10 ³ /μl)	PCV (%)	Hb(g/dl)
MC	5.45±0.18	5.35±0.17	63.5±2.22	18.1±0.91
NC	2.29±0.13	11.1±0.32	24.0±2.04	8.45±0.52
CQ	4.45±0.19 ^a	6.69±0.18 ^a	55.2±3.32 ^a	14.7±0.77 ^a
KT	3.29±0.17 ^b	8.85±0.19 ^b	41.0±3.43 ^b	11.4±0.52 ^b
A/L	4.21±0.22 ^a	6.80±0.21 ^a	52.7±3.21 ^a	14.1±0.59 ^a
KT/A/L	5.33±0.21 ^{cd}	5.00±0.16 ^{cd}	60.4±3.81 ^{cd}	17.5±0.83 ^{cd}

With the folowing referring to : MC: Normal control; NC: Negative control; CQ: Chloroquine; KT: Ketotifen, A/L: Artemether/lumefantrine, KT/A/L: Ketotifen/Artemether/Lumefantrine; TG: Triglyceride; CHOL: Total cholesterol; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; n=5; Values are expressed as M±SEM, ^ap<0.01 when compared to NC; ^bp<0.05 when compared to NC; ^cp<0.001 when compared to NC; ^dp<0.01 when compared to CQ.

DISCUSSION

The development of new drugs is a long and complex process with extremely high investment and small expectation of success. In recent years, there was a significant decline in the number of new drugs approved for clinical use. This necessitates the repurposing of already approved drugs, for new indications other than their initial indications. This strategy reduces costs and research time considerably [22]. This study evaluates the possibility of repurposing KT as an antimalaria drug in combination with A/L on *P. berghei* infected mice. The rodent parasite; *P. berghei* has been used for studying the activity of antimalarial drug candidates in mice [23]. Rodent models of antimalarial study have been validated through the identification of several conventional antimalarial drugs including quinine and more recently artemisinin derivatives [24]. The in vivo antiplasmodial activity of KT/A/L was evaluated using curative, suppressive and suppression test which are validated tests for the assessment of antimalaria drug candidates. Percent parasitemia inhibition and mean survival time were calculated from the curative, suppression, and prophylactic tests with reference to other studies [25, 26]. In this study, antiplasmodial evaluation of KT/A/L shows reductions in

percentage parasitemia levels with increased percentage parasitemia inhibition in the suppressive and curative tests. In the prophylactic test, KT/A/L produced time-related reductions in percentage parasitemia levels and increased percentage parasitemia inhibitions. Malaria associated mortality is a challenge that is prevalent in malaria endemic regions primarily developing nations. MST is experimentally used to assess the ability of antimalarial candidate drugs to prevent or reduced mortality in *plasmodium* parasitized rodents [27]. In this study, KT/A/L increased MST in the suppressive, curative and prophylactic tests best than individual dose of KT and A/L. Anemia is a common malaria complication prevalent in children and pregnant women in malaria endemic regions [28]. *P. berghei* infected mice suffer from anemia because of erythrocyte destruction, either by parasite multiplication or by spleen reticuloendothelial cell action as the presence of many abnormal erythrocytes stimulates the spleen to produce many phagocytes [29]. The current study observed anemia in untreated parasitized mice (Negative control) characterized by decreased RBC, PCV, HB with increased WBC levels. However, KT/A/L produced reduction in anemia characterized by increased RBC, PCV, HB and decreased WBC levels. KT/A/L produced

the best effects on the aforementioned biochemical parameters than individual doses of KT and A/L. Emerging studies suggest that routine laboratory measurement of lipids could be a good and reliable adjunct in the early diagnosis of malaria especially in malaria endemic areas [30]. This study observed impaired lipid profile characterized by elevated TG, CHOL, and LDL-C and decreased HDL levels in negative control. This observation is consistent with altered lipid profile reported in previous findings [31]. However, lipid levels were restored in parasitized rats treated with KT/A/L. This study shows that KT may be repurposed in combination with A/L for the treatment of malaria. The observation in this study can be correlated with a study that reported improved antimalarial activity when KT was co-administered with CQ [17]. The observation in this study can also be compared with increased antimalarial activity when KF was co-administered with CQ and sulphadoxine/pyrimethamine [15]. The precise mechanism by which KT produced antiplasmodial effect has not been elucidated. However, as an antihistamine, it blocks H1 receptors, stabilizes mast cells, and inhibits eosinophil accumulation and degranulation which further stabilizes cell membrane [9]. **Conclusion:** This study

shows that KT may be repurposed in combination with A/L for the treatment of malaria

CONCLUSION

This study shows that A/L/T may be an effective treatment for malaria. We recommend further studies in humans.

ACKNOWLEDGMENTS

None.

AUTHORS' CONTRIBUTIONS

The participation of each author corresponds to the criteria of authorship and contributorship emphasized in the [Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals of the International Committee of Medical Journal Editors](#). Indeed, all the authors have actively participated in the redaction, the revision of the manuscript, and provided approval for this final revised version.

COMPETING INTERESTS

The authors declare no competing interests with this case.

FUNDING SOURCES

None.

REFERENCES

- [1] Mandal A. News Medical- Life sciences and Medicine. Malaria Epidemiology. Retrieved from <http://www.news-medical.net/health/Malaria-Epidemiology.aspx>, 2013.
- [2] WHO, "World Health Organization, 2019. World Malaria Report," <https://www.who.int/malaria/en/>.
- [3] Eastman RT, Pattaradilokrat S, Raj DK, Dixit S, Deng B, Miura K et al., A Class of Tricyclic Compounds Blocking Malaria Parasite Oocyst Development and Transmission Antimicrob Agents and Chem, 2013; 57:425–435
- [4] Penna-Coutinho J, Aguiar AC, Krettli AU. Commercial drugs containing flavonoids are active in mice with malaria and *in vitro* against chloroquine-resistant *Plasmodium falciparum* Mem Inst Oswaldo Cruz, Rio de Janeiro, 113(12): e180279, 2018
- [5] Ashburn T.T., Thor K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 2004;3(8):673–683
- [6] Car B.D. In: Polypharmacology in Drug Discovery. Peters J.-U., editor. Wiley; 2012
- [7] Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 2004;3(8):711–715
- [8] Nowak-Sliwinski P, Scapozza L, Altaba AR Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer BBA - Rev on Can 2019; 1871 434–454
- [9] Montazeri M, Rezaei K, Ebrahimzadeh MA, Sharif IM, Sarvi S, Ahmadpour E, Rahimi MT, Moreira de Oliveira EA, Lang KL, Drug Repositioning: Concept, Classification, Methodology, and Importance in Rare/Orphans and Neglected Diseases Journal of Appl Pharm Sci 2018; 8 (08), 157-165
- [10] Grahnen A, Lonnebo A, Beck O, Eckernas SA, Dahlstrom B, Lindstrom B. 1992. Pharmacokinetics of ketotifen after oral administration to healthy male subjects. Biopharm. Drug Dispos. 13:255–262
- [11] Milner E, Sousa J, Pybus B, Auschwitz J, Caridha D, Gardner S et al., Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy. Eur. J. Drug Metab. Pharmacokinet. 2012 Mar;37(1):17-22
- [12] Basco LK, Ringwald P, Le Bras J. 1991. Chloroquine-potentiating action of antihistaminics in *Plasmodium falciparum* *in vitro*. Ann. Trop. Med. Parasitol. 191; 85:223–228.
- [13] Quan H, Tang LH. 2008. *In vitro* potentiation of chloroquine activity in *Plasmodium falciparum* by ketotifen and cyproheptadine. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 26:338–342. (In Chinese.)
- [14] Singh N, Puri SK. Interaction between chloroquine and diverse pharmacological agents in chloroquine resistant *Plasmodium yoelii nigeriensis*. Acta Trop. 2000; 77:185–193.
- [15] Ibrahim AM, Elhag ER, Mustafa SE. Ketotifen in treatment of uncomplicated falciparum malaria. Saudi Med J. 2000;21(3):257-65
- [16] Sirima SB, Ogutu B, Lusingu JPA, et al. Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated *Plasmodium falciparum* malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Lancet Infect Dis. 2016;16(10):1123-1133.
- [17] You L, Ni B, Cao HM. Effects of low dose of ketotifen and chloroquine combination on the infrastructure of chloroquine resistant strain of *Plasmodium yoelii*. J Shanghai Univ. 2000;4(4):338-42.
- [18] Somsak V, Damkaew A, and Onrak P Antimalarial Activity of Kaempferol and Its Combination with Chloroquine in *Plasmodium berghei* Infection in Mice. Jour of Path 2018; 2018;1- 7

- [19] Ryley, J.F. and Peters, W. The antimalarial activity of some quinolone esters. *Ann. Trop. Med. Parasitol.* 1970; **84**: 209-222.
- [20] Knight, D.J. and Peters, W. The antimalarial action of N-Benzyl oxydihydrotriazines and the studies on its mode of action. *Ann of Trop Med and Par.* 1980; **74**: 393-404.
- [21] Peters, W. Rational methods in the search for antimalarial drugs. *Trans. R. Soc. Trop. Med. Hyg.* **1967**; **61**: 400-410.
- [22] Moreira de Oliveira EA, Lang KL. Drug Repositioning: Concept, Classification, Methodology, and Importance in Rare/Orphans and Neglected Diseases *Jour of Appl Pharm Sci* 2016 8(08), 157-165
- [23] Thomas AM, Van Der Wel AM, Thomas AW, Janse CJ, Waters AP (1998). Transfection systems for animal models of malaria. *Parasitol. Today*, 14: 248-249.
- [24] David AF, Philip JR, Simon IC, Reto B, Solomon N (2004). Antimalarial drug discovery: Efficacy models for compound screening. *Nassture Rev.*, 3: 509-520
- [25] Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. *Nat Rev Drug Discov.* 2004;3(6):509–520.
- [26] Tarkang PA, Appiah-Opong R, Ofori MF, Ayong LS, Nyarko AK. Application of multi-target phytotherapeutic concept in malaria drug discovery: a systems biology approach in biomarker identification. *Biomark Res.* 2016;4(1):25.
- [27] Olanlokun JO, Babarinde CO and Olorunsogo O. O. Toxicity of *Anchomanes difformis*, An Antimalarial Herb in Murine Models *Eur Jour of Med Plants* 2017; 20(3): 1-13
- [28] Saxena R, Bhatia A, Midha K, Debnath M, Kaur P. Malaria: A Cause of Anemia and Its Effect on Pregnancy. *World J Anemia.* 2017;1(2):51-62.
- [29] Chinchilla M, Guerrero O, Abarca G, Barrios M, Castro O. An in vivo model to study the anti-malaria capacity of plant extracts. *Rev Biol Trop.* 1998;46:1–7.
- [30] Sirak S, Fola AA, Worku L, Biadgo B. Malaria parasitemia and its association with lipid and hematological parameters among malaria-infected patients attending at Metema Hospital, Northwest Ethiopia. *Path and Lab Med Intern.* 2016;8:43-50.
- [31] Adekunle A.S., Adekunle O.C., Egbewale B.E Serum status of selected biochemical parameters in malaria: An animal model. *Biomed Res* 2007; 18 (2): 109-113.